Gibson Oncology has licensed three drugs, invented by the NIH and Purdue University which are now in clinical trials.
LMP744, LMP400, LMP776.
In addition, Gibson has invented a class of Aza Indenoisoquinolines suitable for oral administration.
Mechanisms of Action (1)
Non-camptothecin Topoisomerase (Top1) activity.
cMYC activity via G-Quadruplex.
Mechanisms of Action (2)
Selectively target homologous recombinant deficient (HRD) and Schalfen11 positive cancers and have “synergistic cytotoxicity” with PARP inhibitors.
Mechanisms of Action (3)
“Are not effected by many efflux drug transporters including key ones found at the BBB”… (NIH).
The NCI has shown these drugs to have encouraging results in phase I clinical trials for solid tumors and lymphomas.
In phase I clinical trials, even patients who have failed 7 or 8 drugs have shown “prolonged stabilization of disease with prior progression on irinotecan”… (NIH).
Gibson animal studies have shown that LMP400 works in multiple kinds of PTEN-deficient tumors.
